Emergent BioSolutions Announces Strategic Operational Changes to Stabilize Financial PositionGlobeNewsWire • 05/01/24
Emergent BioSolutions Releases New Survey Findings Underscoring the Need to Continue Expanding Access & Increasing Awareness to NaloxoneGlobeNewsWire • 05/01/24
Emergent BioSolutions to Release First Quarter 2024 Financial Results & Conduct Conference Call on May 1, 2024GlobeNewsWire • 04/22/24
Emergent BioSolutions Continues to Broaden Access, Awareness and Availability of NARCAN® Nasal Spray to Help Save Lives from the Ongoing Opioid CrisisGlobeNewsWire • 03/28/24
Emergent BioSolutions Receives NAI Status for Baltimore Bayview Manufacturing FacilityGlobeNewsWire • 03/25/24
Emergent Biosolutions (EBS) Reports Q4 Loss, Tops Revenue EstimatesZacks Investment Research • 03/06/24
Emergent BioSolutions to Release Fourth Quarter & Full Year 2023 Financial Results, and Conduct Conference Call on March 6, 2024GlobeNewsWire • 02/29/24
Emergent BioSolutions Appoints Industry Leader Joseph C. Papa as New President and CEOGlobeNewsWire • 02/21/24
Emergent BioSolutions to Present at the 42nd Annual J.P. Morgan Healthcare Conference on January 11, 2024GlobeNewsWire • 01/09/24
Emergent Biosolutions (EBS) Reports Q3 Loss, Tops Revenue EstimatesZacks Investment Research • 12/11/23
Emergent BioSolutions Receives $75 Million Contract Option from BARDA to Procure Doses of CYFENDUS™ (Anthrax Vaccine Adsorbed, Adjuvanted)GlobeNewsWire • 11/28/23
Emergent BioSolutions Receives NYSE Notice Regarding Delayed Form 10-Q FilingGlobeNewsWire • 11/24/23